Meta-analysis reaffirms safety, efficacy of intermittent biologic use
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.
Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.
Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.
In recognition of Rosacea Awareness Month, Dermatology Times is reviewing research and strides in rosacea treatment over the last decade.
Test your knowledge to see if your patients would consider you an efficient texter.
Research from the GW School of Medicine and Health Sciences was recently published in the Journal of Drugs in Dermatology.
Dermatology Times is pleased to introduce one of our newest partners, Spherix Global Insights. Learn more about their vision and plans to leverage knowledge to…
What are your rights in the instance a colleague defames you online or on social media? David Goldberg, MD, JD, shares legal advice in our…
The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.